APA (7th ed.) Citation

Y, S., D, Y., K, M., T, O., Y, Y., H, K., . . . K, K. (2026). Nivolumab in combination with radiotherapy for unresectable advanced or recurrent gastric cancer (CIRCUIT trial): A 5-year update of the progression-free survival and local control outcomes. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 219, 111494. https://doi.org/10.1016/j.radonc.2026.111494

Chicago Style (17th ed.) Citation

Y, Suzuki, et al. "Nivolumab in Combination with Radiotherapy for Unresectable Advanced or Recurrent Gastric Cancer (CIRCUIT Trial): A 5-year Update of the Progression-free Survival and Local Control Outcomes." Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology 219 (2026): 111494. https://doi.org/10.1016/j.radonc.2026.111494.

MLA (9th ed.) Citation

Y, Suzuki, et al. "Nivolumab in Combination with Radiotherapy for Unresectable Advanced or Recurrent Gastric Cancer (CIRCUIT Trial): A 5-year Update of the Progression-free Survival and Local Control Outcomes." Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, vol. 219, 2026, p. 111494, https://doi.org/10.1016/j.radonc.2026.111494.